The report provides a detailed analysis essential for establishing a Clavulanic Acid production plant. It encompasses all critical aspects necessary for Clavulanic Acid production, including the cost of Clavulanic Acid production, Clavulanic Acid plant cost, Clavulanic Acid production costs, and the overall Clavulanic Acid production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Clavulanic Acid production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Clavulanic acid is a beta-lactam compound that is mainly used in the pharmaceutical industry to enhance the effectiveness of certain antibiotics. It is primarily combined with beta-lactam antibiotics like amoxicillin to overcome bacterial resistance. It helps block beta-lactamase enzymes produced by resistant bacteria, allowing the antibiotic to work properly.
It is widely used to treat respiratory tract infections, urinary tract infections, skin infections, and dental infections. It is utilised in fixed-dose antibiotic combinations in hospitals and outpatient care to enhance their effectiveness against resistant bacterial infections. It also plays an important role in clinical research and drug formulation, supporting the development of improved antibacterial therapies against resistant microorganisms.
The primary factor that drives the market for Clavulanic Acid is its demand as a beta-lactamase inhibitor in combination with penicillin-type antibiotics to treat resistant bacterial infections. Its application as a medication in therapies for respiratory tract, urinary tract, skin, and soft tissue infections further promotes demand in the healthcare and pharmaceutical industries.
The rising prevalence of antibiotic resistance and the continued need for effective combination antibiotics further contribute to market expansion. Industrial Clavulanic acid procurement largely depends on factors including the availability and cost of fermentation-based raw materials, strict regulatory compliance, and quality standards. In addition, improvements in fermentation and purification technologies, dependable supplier networks, sustainability practices, and well-managed logistics also play a major role in influencing global procurement trends for Clavulanic acid.
Raw Material for Clavulanic Acid Production
According to the Clavulanic Acid production plant project report, the major raw materials for Clavulanic Acid production includes Streptomyces clavuligerus.
Production Process of Clavulanic Acid
The extensive Clavulanic Acid production cost report consists of the following industrial production process:
- Production via Fermentation: The production process of Clavulanic acid begins with fermenting the bacterium Streptomyces clavuligerus in large-scale bioreactors. In this method, the bacterium naturally produces the compound as a secondary metabolite under controlled conditions of nutrients, temperature, and aeration. Once fermentation is complete, workers harvest the broth by filtration to separate the solid biomass containing the acid. Then, the acid is extracted using organic solvents to pull out the clavulanic acid into a concentrated form. Further, this extract undergoes purification through chromatography and crystallisation steps to isolate pure clavulanic acid, which is finally dried and formulated into a stable powder ready for pharmaceutical use.
Clavulanic Acid is a beta-lactamase inhibitor that is naturally produced by the bacterium Streptomyces clavuligerus. The molecular formula of the compound is C8H9NO5, and its molecular mass is 199.16 g/mol. It appears as a white to off-white hygroscopic crystalline powder or solid at room temperature and is odourless. The compound is soluble in water and exhibits good solubility in polar solvents. The melting point of clavulanic acid is around 117.5-118 degree Celsius, and its boiling point is around 545.8 degree Celsius. The compound is highly unstable and sensitive to both moisture and heat, and is stored at 4 degree Celsius in dry conditions to maintain stability. It is most commonly used in combination with amoxicillin under the trade name Augmentin or with ticarcillin as Timentin for treating bacterial infections caused by beta-lactamase-producing organisms. It is recommended that treatment with clavulanic acid combinations be reserved for infections likely caused by beta-lactamase-producing strains and should not normally exceed 14 days.